Edit Entry

Matthew C. Havrda, PhD

Assistant Professor of Molecular and Systems Biology

Molecular and Systems Biology

University of Maine: Graduate School of Biomedical Sciences and Engineering, Ph.D.

Norris Cotton Cancer Center
Program in Experimental and Molecular Medicine

Contact Information:

Professional Interests:

Neurodegenerative Diseases
Glial Cell Biology
Brain Cancer

Rotations and Thesis Projects:

Parkinson's disease
Translational Neurobiology

Grant Information:

Target Validation Award: The Michael J. Fox Foundation for Parkinson's Disease Research
Dartmouth SYNERGY Scholars Award
The Hitchcock Foundation
NIN/NINDS 1F32NS059126-01A1
NIH-NIEHS 1R01ES024745: Mechanisms of rotenone-induced neuroinflammation and Parkinsonism in aging mice

Courses Taught:

Course Co-Director, Neurobiology of Disease (PEMM 211)


Dr. Havrda is a neurobiologist interested in characterizing the molecular basis of brain disorders, especially Parkinson’s disease and its various pathologic manifestations. He received his Ph.D. in 2006 from the Graduate School of Biomedical Science and Engineering of the University of Maine at the Maine Medical Center Research Institute. Dr. Havrda is an Assistant Professor at the Geisel School of Medicine at Dartmouth affiliated with the Parkinson’s Center at Dartmouth working at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Throughout his career he has published numerous research reports and book chapters while receiving academic awards including the Ian Sinclair Scholarship, the Apollon Valakis Scholarship and the Doris G. Alexander Memorial Scholarship. More recently Dr. Havrda has received prestigious young investigator awards including the Ruth L. Kirschstein National Research Service Award, the Dartmouth SYNERGY Scholar Award for Clinical and Translational Research, and a Target Validation Award from the Michael J. Fox Foundation. Dr. Havrda’s research program is focused on characterizing the molecular basis of neuroinflammation during the progression of Parkinson’s disease both in cellular and animal models as well as in biofluids and post-mortem tissues obtained from Parkinson’s patients. Such studies are expected to provide new platforms from which to discover, monitor and evaluate diagnostic indicators and therapeutic targets.

Selected Publications:


Characterizing the heterogeneity in 5-aminolevulinic acid-induced fluorescence in glioblastoma.
Almiron Bonnin DA, Havrda MC, Lee MC, Evans L, Ran C, Qian DC, Harrington LX, Valdes PA, Cheng C, Amos CI, Harris BT, Paulsen KD, Roberts DW, Israel MA
J Neurosurg. 2019 May 24;:1-9. doi: 10.3171/2019.2.JNS183128. Epub 2019 May 24.
PMID: 31125970

Glioma Cell Secretion: A Driver of Tumor Progression and a Potential Therapeutic Target.
Almiron Bonnin DA, Havrda MC, Israel MA
Cancer Res. 2018 Nov 1;78(21):6031-6039. doi: 10.1158/0008-5472.CAN-18-0345. Epub 2018 Oct 17.
PMID: 30333116

Inflammasomes: An Emerging Mechanism Translating Environmental Toxicant Exposure Into Neuroinflammation in Parkinson's Disease.
Anderson FL, Coffey MM, Berwin BL, Havrda MC
Toxicol Sci. 2018 Nov 1;166(1):3-15. doi: 10.1093/toxsci/kfy219.
PMID: 30203060

NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease.
von Herrmann KM, Salas LA, Martinez EM, Young AL, Howard JM, Feldman MS, Christensen BC, Wilkins OM, Lee SL, Hickey WF, Havrda MC
NPJ Parkinsons Dis. 2018;4:24. doi: 10.1038/s41531-018-0061-5. Epub 2018 Aug 15.
PMID: 30131971

Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia.
Almiron Bonnin DA, Havrda MC, Lee MC, Liu H, Zhang Z, Nguyen LN, Harrington LX, Hassanpour S, Cheng C, Israel MA
Oncogene. 2018 Feb 22;37(8):1107-1118. doi: 10.1038/onc.2017.404. Epub 2017 Nov 20.
PMID: 29155422

Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice.
Martinez EM, Young AL, Patankar YR, Berwin BL, Wang L, von Herrmann KM, Weier JM, Havrda MC
Toxicol Sci. 2017 Sep 1;159(1):64-75. doi: 10.1093/toxsci/kfx117.
PMID: 28903492

ID2 promotes survival of glioblastoma cells during metabolic stress by regulating mitochondrial function.
Zhang Z, Rahme GJ, Chatterjee PD, Havrda MC, Israel MA
Cell Death Dis. 2017 Feb 16;8(2):e2615. doi: 10.1038/cddis.2017.14. Epub 2017 Feb 16.
PMID: 28206987

Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas.
Almiron Bonnin DA, Ran C, Havrda MC, Liu H, Hitoshi Y, Zhang Z, Cheng C, Ung M, Israel MA
Mol Cancer Ther. 2017 Apr;16(4):705-716. doi: 10.1158/1535-7163.MCT-16-0616. Epub 2017 Jan 30.
PMID: 28138037

Phosphorylation Regulates Id2 Degradation and Mediates the Proliferation of Neural Precursor Cells.
Sullivan JM, Havrda MC, Kettenbach AN, Paolella BR, Zhang Z, Gerber SA, Israel MA
Stem Cells. 2016 May;34(5):1321-31. doi: 10.1002/stem.2291. Epub 2016 Feb 1.
PMID: 26756672

Inhibitor of differentiation 4 (ID4): From development to cancer.
Patel D, Morton DJ, Carey J, Havrda MC, Chaudhary J
Biochim Biophys Acta. 2015 Jan;1855(1):92-103. doi: 10.1016/j.bbcan.2014.12.002. Epub 2014 Dec 12.
PMID: 25512197

View more publications on PubMed